Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 13Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 3Smoldering Multiple Myeloma 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Hodgkin Disease 1Fatigue 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × dexamethasone 21-phosphate × 90 days × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡